Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CI-994 plus Gemcitabine in Advanced NSCLC
NCT00005093Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 1999
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of tacedinaline in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Dec 1999; status: completed.
02
Drugs
tacedinaline
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00005093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005093.